Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai Hopes To Resume Trials On New Alzheimer's Drug (Japan)

This article was originally published in PharmAsia News

Executive Summary

Eisai reports it will resume clinical trials this fiscal year on E2012, the planned-for successor to its Alzheimer's drug Aricept. Eisai began phase I trials on E2012 in 2006 in the U.S., but suspended the trials earlier this year after concomitant trials in rats indicated that E2012 could cause clouding of the eyes. The drug firm has since done experiments with rats and discovered that the eye problem developed because E2012 caused blood cholesterol levels to fall too far. The tests also found that using E2012 in a lower dose kept the blood cholesterol levels from declining too much. Eisai has talked with the U.S. Food and Drug Administration and hopes to resume clinical trials before the end of the current fiscal year after finding a blood marker that can be used to monitor safety. (Click here for more - May Require Paid Subscription

You may also be interested in...

Rethinking Alzheimer's: Mapping Out an Approval Process

Drug companies involved in Alzheimer's disease research are a little fed up with FDA. Some, like Wyeth, believe the agency should put Alzheimer's research higher up on its priority list and allow the use of surrogate endpoints for clinical trials. But FDA says that no validated surrogate exists for Alzheimer's, and until it has hard data from products in development, it is loath to recommend one. A recent reorganization of the agency's neurology group may provide an opening to press home those arguments.

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.

AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval

A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts